Logo-InveniAI.png
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
06 nov. 2019 08h00 HE | InveniAI
GUILFORD, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference
28 oct. 2019 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024
08 oct. 2019 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces the Appointment of Two New Board Members
02 oct. 2019 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
01 oct. 2019 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference
05 sept. 2019 08h00 HE | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
21 août 2019 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
Logo FINAL.png
Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
20 août 2019 09h00 HE | Emendo Biotherapeutics
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics today announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
09 août 2019 08h00 HE | VBI Vaccines, Inc.
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
08 août 2019 08h30 HE | BioCardia, Inc.
SAN CARLOS, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...